Literature DB >> 23683669

Urine screening by Seldi-Tof, followed by biomarker identification, in a Brazilian cohort of patients with renal cell carcinoma (RCC).

Gilda Alves1, Denise A Pereira, Vanessa Sandim, Antonio A Ornellas, Niko Escher, Christian Melle, Ferdinand von Eggeling.   

Abstract

PURPOSE: To screen proteins/peptides in urine of Renal Cell Carcinoma (RCC) patients by SELDI-TOF (Surface Enhanced Laser Desorption Ionization - Time of Flight) in search of possible biomarkers.
MATERIAL AND METHODS: Sixty-one urines samples from Clear Cell RCC and Papillary RCC were compared to 29 samples of control urine on CM10 chip. Mass analysis was performed in a ProteinChip Reader PCS 4,000 (Ciphergen Biosystems, Fremont, CA) with the software Ciphergen Express 3.0. All chips were read at low and at high laser energy. For statistical analysis the urine samples were clustered according to the histological classification (Clear Cell and Papillary Carcinoma). For identification urine was loaded on a SDS PAGE gel and bands of most interest were excised, trypsinized and identified by MS/MS. Databank searches were performed in Swiss-Prot database using the MASCOT search algorithm and in Profound.
RESULTS: Proteins that were identified from urine of controls included immunoglobulin light chains, albumin, secreted and transmembrane 1 precursor (protein K12), mannan-binding lectin-associated serine protease-2 (MASP-2) and vitelline membrane outer layer 1 isoform 1. Identification of immunoglobulins and isoforms of albumin are quite common by proteomics and therefore cannot be considered as possible molecular markers. K12 and MASP-2 play important physiological roles, while vitellite membrane outer layer 1 role is unknown since it was never purified in humans.
CONCLUSIONS: The down expression of Protein K-12 and MASP-2 make them good candidates for RCC urine marker and should be validated in a bigger cohort including the other less common histological RCC subtypes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23683669     DOI: 10.1590/S1677-5538.IBJU.2013.02.12

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


  4 in total

Review 1.  Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma.

Authors:  Zofia Felicja Bielecka; Anna Małgorzata Czarnecka; Cezary Szczylik
Journal:  Front Oncol       Date:  2014-07-25       Impact factor: 6.244

2.  Evaluation of Protein Profiling in a Cohort of Egyptian Population with Renal Cell Carcinoma and Benign Kidney Neoplasms.

Authors:  Noha Said Kandil; Rasha Abdelmawla Ghazala; Rania Mohamed El Sharkawy; Tamer Abou Youssif; Noha Noha Abouseda
Journal:  Asian Pac J Cancer Prev       Date:  2019-07-01

3.  Posttranslational Modifications Pattern in Clear Cell Renal Cell Carcinoma.

Authors:  Corina Daniela Ene; Mircea Nicolae Penescu; Simona Roxana Georgescu; Mircea Tampa; Ilinca Nicolae
Journal:  Metabolites       Date:  2020-12-27

4.  Urinary signatures of Renal Cell Carcinoma investigated by peptidomic approaches.

Authors:  Clizia Chinello; Marta Cazzaniga; Gabriele De Sio; Andrew James Smith; Erica Gianazza; Angelica Grasso; Francesco Rocco; Stefano Signorini; Marco Grasso; Silvano Bosari; Italo Zoppis; Mohammed Dakna; Yuri E M van der Burgt; Giancarlo Mauri; Fulvio Magni
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.